These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22935083)

  • 1. The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
    Krysiak R; Gdula-Dymek A; Okopien B
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):198-202. PubMed ID: 22935083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose.
    Krysiak R; Okopien B
    Atherosclerosis; 2012 Dec; 225(2):403-7. PubMed ID: 23107042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
    Okopień B; Krysiak R; Herman ZS
    J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
    Krysiak R; Gdula-Dymek A; Marek B; Okopień B
    Endokrynol Pol; 2015; 66(3):224-30. PubMed ID: 26136131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
    Krysiak R; Gdula-Dymek A; Okopien B
    Am J Cardiol; 2011 Apr; 107(7):1010-1018.e1. PubMed ID: 21276586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
    Krysiak R; Gdula-Dymek A; Marek B; Okopień B
    Endokrynol Pol; 2016; 67(2):190-6. PubMed ID: 26884290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance.
    Krysiak R; Gdula-Dymek A; Okopień B
    Pharmacol Rep; 2013; 65(2):429-34. PubMed ID: 23744427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels.
    Krysiak R; Zmuda W; Okopien B
    J Intern Med; 2012 Jan; 271(1):32-42. PubMed ID: 21623963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose.
    Krysiak R; Okopien B
    Metabolism; 2013 Jan; 62(1):39-43. PubMed ID: 22841520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report.
    Krysiak R; Okopien B
    Atherosclerosis; 2010 Nov; 213(1):325-8. PubMed ID: 20705292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance.
    Krysiak R; Gdula-Dymek A; Okopień B
    Pharmacol Rep; 2013; 65(5):1311-6. PubMed ID: 24399727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory and monocyte-suppressing effects of simvastatin in patients with impaired fasting glucose.
    Krysiak R; Gdula-Dymek A; Scieszka J; Okopień B
    Basic Clin Pharmacol Toxicol; 2011 Feb; 108(2):131-7. PubMed ID: 20955358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
    Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
    J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
    Ren JY; Chen H; Luo Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb; 33(2):122-6. PubMed ID: 15924805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocyte-suppressing effects of simvastatin in patients with isolated hypertriglyceridemia.
    Krysiak R; Okopien B
    Eur J Intern Med; 2013 Apr; 24(3):255-9. PubMed ID: 23159435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
    Filippatos TD; Elisaf MS
    Expert Opin Pharmacother; 2011 Aug; 12(12):1945-58. PubMed ID: 21736529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
    Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.
    Wang TD; Chen WJ; Lin JW; Cheng CC; Chen MF; Lee YT
    Atherosclerosis; 2003 Oct; 170(2):315-23. PubMed ID: 14612213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
    Lazich I; Sarafidis P; de Guzman E; Patel A; Oliva R; Bakris G
    Diabetes Obes Metab; 2012 Feb; 14(2):181-6. PubMed ID: 21955403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.